Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Insmed Inc (INSM)

Insmed Inc (INSM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Insmed Inc 700 US Highway 202/206 Bridgewater NJ 08807 USA

www.insmed.com Employees: 1,271 P: 908-977-9900

Sector:

Medical

Description:

Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company's inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.

Key Statistics

Overview:

Market Capitalization, $K 31,681,704
Enterprise Value, $K 32,230,054
Shares Outstanding, K 213,273
Float, K 206,875
% Float 97.00%
Short Interest, K 11,888
Short Float 5.57%
Days to Cover 4.22
Short Volume Ratio 0.51
% of Insider Shareholders 3.00%

Financials:

Annual Sales, $ 363,710 K
Annual Net Income, $ -913,770 K
Last Quarter Sales, $ 142,340 K
Last Quarter Net Income, $ -370,020 K
EBIT, $ -1,152 M
EBITDA, $ -1,132 M

Growth:

1-Year Return 85.79%
3-Year Return 620.77%
5-Year Return 263.20%
5-Year Revenue Growth 166.51%
5-Year Earnings Growth -85.05%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.75 on 10/30/25
Next Earnings Date 02/19/26 [BMO]
Earnings Per Share ttm -6.19
EPS Growth vs. Prev Qtr -2.94%
EPS Growth vs. Prev Year -37.80%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 03/03/11

INSM Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -183.55%
Return-on-Assets % -54.63%
Profit Margin % -251.24%
Debt/Equity 0.57
Price/Sales 63.25
Price/Cash Flow N/A
Price/Book 33.73
Book Value/Share 4.43
Interest Coverage -9.72
60-Month Beta 1.11
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar